Oragenics Inc (OGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oragenics Inc (OGEN) has a cash flow conversion efficiency ratio of -0.356x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.20 Million) by net assets ($6.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oragenics Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Oragenics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OGEN liabilities breakdown for a breakdown of total debt and financial obligations.
Oragenics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oragenics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jost AG
MU:JOX
|
N/A |
|
Millennium Food-Tech LP
TA:MIFT
|
N/A |
|
GENERIC GOLD CORP.
F:1WD
|
N/A |
|
Inventronics Ltd
V:IVX
|
-0.005x |
|
CAB Payments Holdings Ltd
LSE:CABP
|
-0.303x |
|
Performance One AG
F:PO1
|
N/A |
|
Northern Lion Gold Corp
V:NL
|
0.065x |
|
SThree plc
LSE:STEM
|
0.183x |
Annual Cash Flow Conversion Efficiency for Oragenics Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of Oragenics Inc from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see Oragenics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.28 Million | $-9.25 Billion | -1116.524x | -2851.71% |
| 2024-12-31 | $-211.88K | $-8.60 Million | 40.576x | +1863.16% |
| 2023-12-31 | $3.17 Million | $-7.29 Million | -2.301x | -96.59% |
| 2022-12-31 | $13.01 Million | $-15.23 Million | -1.171x | -130.17% |
| 2021-12-31 | $26.49 Million | $-13.47 Million | -0.509x | +49.47% |
| 2020-12-31 | $16.84 Million | $-16.95 Million | -1.006x | -33.27% |
| 2019-12-31 | $17.23 Million | $-13.01 Million | -0.755x | -73.68% |
| 2018-12-31 | $20.88 Million | $-9.08 Million | -0.435x | +56.84% |
| 2017-12-31 | $6.32 Million | $-6.36 Million | -1.008x | +57.77% |
| 2016-12-31 | $2.97 Million | $-7.08 Million | -2.386x | -121.11% |
| 2015-12-31 | $4.73 Million | $-5.10 Million | -1.079x | -100.60% |
| 2014-12-31 | $10.34 Million | $-5.56 Million | -0.538x | -25.93% |
| 2013-12-31 | $15.84 Million | $-6.76 Million | -0.427x | +24.35% |
| 2012-12-31 | $9.23 Million | $-5.21 Million | -0.565x | -184.04% |
| 2011-12-31 | $-8.18 Million | $-5.49 Million | 0.672x | -80.21% |
| 2010-12-31 | $-1.90 Million | $-6.45 Million | 3.395x | +254.53% |
| 2009-12-31 | $2.64 Million | $-5.80 Million | -2.197x | -110.15% |
| 2008-12-31 | $-177.25K | $-3.84 Million | 21.637x | +1026.98% |
| 2007-12-31 | $819.88K | $-1.91 Million | -2.334x | -34.13% |
| 2006-12-31 | $1.28 Million | $-2.22 Million | -1.740x | +10.23% |
| 2005-12-31 | $1.77 Million | $-3.43 Million | -1.939x | -185.04% |
| 2004-12-31 | $4.04 Million | $-2.75 Million | -0.680x | -91.94% |
| 2003-12-31 | $3.44 Million | $-1.22 Million | -0.354x | -- |
About Oragenics Inc
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation w… Read more